Cessation of Nucleoside/Nucleotide Analogue Therapy in Chronic Hepatitis B HBeAg-Negative Patients

Abstract: Most patients treated for chronic hepatitis B infection require lifelong treatment with nucleoside/nucleotide analogues (NAs), which inhibit hepatitis B virus (HBV) replication but do not […]

Helicobacter pylori Treatment Regimens: A US Perspective 

Abstract: Helicobacter pylori infects nearly one-third of the US population. H pylori is a significant cause of gastroduodenal disease, including peptic ulcers and cancers. However, rising […]

Approach to Treatment Failure in Inflammatory Bowel Disease

G&H  What are the current options for conventional therapy for inflammatory bowel disease, and what are the typical response rates?  AM  Multiple options have been approved […]

Eliminating Hepatitis C Virus Infection in Indigent Patients

G&H  What is the current goal for eliminating hepatitis C virus, and how close is the United States to achieving it? ET  The World Health Organization […]

Exploring the Potential Chemoprophylactic Role of Carvedilol for Hepatocellular Carcinoma

G&H  What are the notable risk factors for hepatocellular carcinoma? RS  The main risk factor for hepatocellular carcinoma (HCC) is liver cirrhosis. A damaged liver with […]

Dietary Concerns and Patient-Focused Care in Irritable Bowel Syndrome

G&H  What is known about the pathogenesis of irritable bowel syndrome? LC  Irritable bowel syndrome (IBS) is now considered to be a disorder of gut-brain interaction, […]

Managing Patients With Helicobacter pylori Infection

Helicobacter pylori infection affects more than one-half of the global population and almost one-third of the US population. Management of this infection has become more challenging […]

Back to Archive
Millennium Medical Publishing, Inc